GLAXO
GlaxoSmithKline Pharmaceuticals Limited
GSK plc's Indian arm — vaccines and general medicines
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
india-pharma.gsk.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Stock price
₹2566.10
Market cap
43,473 Cr
Stock P/E
40.7
P/B
19.17
Dividend yield
1.6%
ROE (FY26)
45.3%
ROCE (FY26)
61.7%
Operating margin (FY26)
32.5%
Debt / equity (FY26)
0.00
OCF / EBITDA (FY26)
69.0%
OCF / EBITDA (3Y)
81.7%
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
GSK India (GlaxoSmithKline Pharmaceuticals) sells general medicines, vaccines and a growing range of specialty medicines, including cancer treatments, in India.
Company snapshot
17thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
Positives
- ✓Net margin of 27.1% — the business keeps a healthy share of every rupee it earns.
4 more signals from the filings.Sign in free to see them all
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 957 Cr | 805 Cr | 930 Cr | 815 Cr | 1,011 Cr | 949 Cr | 974 Cr | 805 Cr | 980 Cr | 1,041 Cr | 995 Cr | 938 Cr |
| Operating expenses (approx.) | 668 Cr | 587 Cr | 673 Cr | 584 Cr | 689 Cr | 658 Cr | 641 Cr | 554 Cr | 644 Cr | 670 Cr | 644 Cr | 643 Cr |
| EBITDA | 289 Cr | 218 Cr | 257 Cr | 231 Cr | 322 Cr | 292 Cr | 333 Cr | 251 Cr | 336 Cr | 371 Cr | 351 Cr | 296 Cr |
| OPM % | 30.3% | 27.1% | 27.7% | 28.3% | 31.8% | 30.7% | 34.2% | 31.2% | 34.3% | 35.7% | 35.3% | 31.5% |
| Other income | 28 Cr | 28 Cr | 30 Cr | 36 Cr | 35 Cr | 35 Cr | 41 Cr | 44 Cr | 34 Cr | 32 Cr | 36 Cr | 44 Cr |
| Interest | 0.43 Cr | 0.32 Cr | 0.77 Cr | 0.37 Cr | 0.27 Cr | 0.09 Cr | 0.58 Cr | 0.42 Cr | 0.51 Cr | 1 Cr | 0.61 Cr | 0.97 Cr |
| Depreciation | 18 Cr | 17 Cr | 18 Cr | 16 Cr | 17 Cr | 19 Cr | 15 Cr | 16 Cr | 17 Cr | 20 Cr | 13 Cr | 16 Cr |
| Profit before tax | 299 Cr | 65 Cr | 271 Cr | 249 Cr | 344 Cr | 308 Cr | 359 Cr | 279 Cr | 354 Cr | 400 Cr | 373 Cr | 322 Cr |
| Tax % | 27.3% | 30.1% | 28.1% | 26.9% | 26.6% | 25.4% | 26.7% | 26.5% | 27.3% | 26.1% | 25.5% | 26.4% |
| Net profit | 218 Cr | 46 Cr | 194 Cr | 182 Cr | 253 Cr | 230 Cr | 263 Cr | 205 Cr | 257 Cr | 296 Cr | 278 Cr | 237 Cr |
| EPS (₹) | ₹12.84 | ₹9.89 | ₹11.48 | ₹10.76 | ₹14.67 | ₹13.57 | ₹15.52 | ₹12.10 | ₹15.07 | ₹16.54 | ₹16.40 | ₹14.00 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,000 Cr | 2,896 Cr | 3,128 Cr | 3,224 Cr | 3,199 Cr | 3,278 Cr | 3,252 Cr | 3,454 Cr | 3,749 Cr | 3,822 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 2,581 Cr | 2,390 Cr | 2,527 Cr | 2,567 Cr | 2,504 Cr | 2,516 Cr | 2,447 Cr | 2,545 Cr | 2,572 Cr | 2,512 Cr | Sign in free for the trailing twelve months |
| EBITDA | 419 Cr | 506 Cr | 601 Cr | 657 Cr | 695 Cr | 762 Cr | 804 Cr | 909 Cr | 1,177 Cr | 1,309 Cr | Sign in free for the trailing twelve months |
| OPM % | 14.0% | 17.5% | 19.2% | 20.4% | 21.7% | 23.2% | 24.7% | 26.3% | 31.4% | 34.3% | Sign in free for the trailing twelve months |
| Other income | 73 Cr | 55 Cr | 102 Cr | 79 Cr | 111 Cr | 76 Cr | 101 Cr | 123 Cr | 146 Cr | 145 Cr | Sign in free for the trailing twelve months |
| Interest | 0.25 Cr | 0.19 Cr | 0.55 Cr | 6 Cr | 4 Cr | 2 Cr | 2 Cr | 2 Cr | 1 Cr | 3 Cr | Sign in free for the trailing twelve months |
| Depreciation | 26 Cr | 38 Cr | 49 Cr | 83 Cr | 79 Cr | 68 Cr | 66 Cr | 70 Cr | 67 Cr | 66 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 511 Cr | 540 Cr | 683 Cr | 306 Cr | 551 Cr | 2,487 Cr | 841 Cr | 816 Cr | 1,260 Cr | 1,406 Cr | Sign in free for the trailing twelve months |
| Tax % | 34.1% | 35.0% | 34.8% | 69.5% | 34.9% | 31.9% | 27.3% | 27.7% | 26.4% | 26.3% | Sign in free for the trailing twelve months |
| Net profit | 337 Cr | 351 Cr | 445 Cr | 93 Cr | 358 Cr | 1,695 Cr | 611 Cr | 590 Cr | 928 Cr | 1,036 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹39.76 | ₹41.41 | ₹26.29 | ₹5.50 | ₹21.14 | ₹100.04 | ₹36.05 | ₹34.83 | ₹54.52 | ₹54.52 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | 189.2% | 29.9% | 249.8% | 91.8% | 80.8% | 68.9% | Sign in free for the trailing twelve months |
Sign in free for the trailing twelve months
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 85 Cr | 85 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr |
| Reserves | 1,922 Cr | 1,973 Cr | 1,970 Cr | 1,651 Cr | 1,330 Cr | 2,494 Cr | 1,572 Cr | 1,608 Cr | 1,782 Cr | 2,098 Cr |
| Borrowings | 0.99 Cr | 0.58 Cr | 0.18 Cr | 0.02 Cr | — | — | — | — | — | — |
| Other liabilities | 996 Cr | 1,890 Cr | 1,771 Cr | 1,315 Cr | 1,614 Cr | 1,970 Cr | 1,585 Cr | 1,779 Cr | 2,157 Cr | 2,039 Cr |
| Total liabilities | 3,004 Cr | 3,947 Cr | 3,911 Cr | 3,136 Cr | 3,113 Cr | 4,633 Cr | 3,327 Cr | 3,557 Cr | 4,108 Cr | 4,324 Cr |
| Fixed assets (net) | 253 Cr | 250 Cr | 364 Cr | 707 Cr | 341 Cr | 295 Cr | 295 Cr | 297 Cr | 270 Cr | 274 Cr |
| CWIP | 573 Cr | 923 Cr | 1,003 Cr | 120 Cr | 13 Cr | 31 Cr | 20 Cr | 14 Cr | 14 Cr | 33 Cr |
| Investments | 0.06 Cr | 0.06 Cr | 2 Cr | 1 Cr | 1 Cr | 367 Cr | 519 Cr | 814 Cr | 1,119 Cr | 1,392 Cr |
| Inventories | 426 Cr | 500 Cr | 486 Cr | 483 Cr | 547 Cr | 535 Cr | 460 Cr | 525 Cr | 482 Cr | 458 Cr |
| Trade receivables | 171 Cr | 147 Cr | 120 Cr | 100 Cr | 216 Cr | 205 Cr | 192 Cr | 222 Cr | 293 Cr | 273 Cr |
| Cash & bank | 139 Cr | 201 Cr | 99 Cr | 105 Cr | 405 Cr | 286 Cr | 35 Cr | 64 Cr | 539 Cr | 1,102 Cr |
| Other assets | 1,442 Cr | 1,926 Cr | 1,837 Cr | 1,619 Cr | 1,590 Cr | 2,915 Cr | 1,805 Cr | 1,620 Cr | 1,392 Cr | 792 Cr |
| Total assets | 3,004 Cr | 3,947 Cr | 3,911 Cr | 3,136 Cr | 3,113 Cr | 4,633 Cr | 3,327 Cr | 3,557 Cr | 4,108 Cr | 4,324 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 234 Cr | 473 Cr | 409 Cr | 490 Cr | 578 Cr | 811 Cr | 484 Cr | 582 Cr | 1,290 Cr | 903 Cr |
| Cash from investing | 301 Cr | -104 Cr | -153 Cr | -57 Cr | 419 Cr | -405 Cr | 808 Cr | 9 Cr | -46 Cr | 397 Cr |
| Cash from financing | -511 Cr | -307 Cr | -358 Cr | -428 Cr | -696 Cr | -524 Cr | -1,543 Cr | -561 Cr | -769 Cr | -737 Cr |
| Net cash flow | 24 Cr | 62 Cr | -102 Cr | 6 Cr | 300 Cr | -119 Cr | -251 Cr | 29 Cr | 475 Cr | 563 Cr |
| Free cash flow (OCF − Capex) | -70 Cr | 69 Cr | 118 Cr | 335 Cr | 534 Cr | 776 Cr | 440 Cr | 551 Cr | 1,267 Cr | 848 Cr |
Ratios
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 25.5% | 26.2% | 31.9% | 17.1% | 37.0% | 93.5% | 48.4% | 46.0% | 64.6% | 61.7% |
| ROE % | 16.8% | 17.0% | 20.8% | 5.1% | 23.9% | 63.6% | 35.1% | 33.2% | 47.5% | 45.3% |
| Debtor days | 21 | 18 | 14 | 11 | 25 | 23 | 22 | 23 | 28 | 26 |
| Inventory days | 296 | 356 | 258 | 372 | 422 | 318 | 392 | 352 | 351 | 382 |
| Days payable | 194 | 360 | 215 | 275 | 358 | 340 | 364 | 419 | 516 | 476 |
| Cash conversion cycle | 123 | 14 | 57 | 108 | 88 | 1 | 49 | -44 | -137 | -68 |
| OCF / EBITDA % | 55.9% | 93.5% | 68.2% | 74.6% | 83.1% | 106.4% | 60.2% | 64.0% | 109.6% | 69.0% |
| OCF / EBITDA % (3 years) | — | — | 73.2% | 77.8% | 75.7% | 88.9% | 82.8% | 75.8% | 81.5% | 81.7% |
| Debt / equity | 0.0005 | 0.0003 | 0.0001 | 0.0000 | 0.00 | 0.0001 | 0.00 | 0.00 | — | 0.00 |
| Current ratio | 2.32 | 1.36 | 1.38 | 2.04 | 1.78 | 2.30 | 2.04 | 1.98 | 1.89 | 2.13 |
| Net debt / EBITDA | -0.33 | — | -0.16 | -0.16 | -0.58 | -0.38 | -0.04 | -0.07 | -0.46 | -0.84 |